A Phase 2 interventional study of Oral zamicastat in Pulmonary Arterial Hypertension, sponsored by Bial - Portela C S.A.. Completed at 13 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Bial - Portela C S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing zamicastat in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. zamicastat · Pulmonary Arterial Hypertension.
Among the 11 studies testing zamicastat in Pulmonary Arterial Hypertension, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 2 in phase 2, and was the 3rd registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →None of the 11 studies testing zamicastat in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 44 across the 11 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Bial - Portela C S.A. is the lead sponsor of 136 studies on the registry; 1 is open to participants now.
12 studies in Pulmonary Arterial Hypertension by Bial - Portela C S.A.: none open now, none under way, none of them phase 3. Of 12 finished, 1 (8%) have results posted.
Among the 12 studies in Pulmonary Arterial Hypertension by Bial - Portela C S.A., this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 2 in phase 2, and was the 3rd registered.
Bial - Portela C S.A.’s Pulmonary Arterial Hypertension studies by the year they started, since 2015.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing zamicastat in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bial - Portela C S.A.’s 12 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Study evaluates the pharmacokinetic (PK) profile of different zamicastat doses in Pulmonary arterial hypertension (PAH) patients to find the most promising therapeutic dosage range for the treatment of PAH disease
This is an open-label, multi-centre study in patients with PAH who are currently on stable treatment with at least one PAH medication. It is planned to evaluate the PK profile (24 hour profile and trough levels) and the safety, tolerability and efficacy of four different zamicastat doses. Each patient will start treatment with the lowest dose (50 mg zamicastat once daily) and the dose will be up-titrated to the individual highest tolerated dose (HTD) i.e. up to 200 mg zamicastat once daily.
A data safety monitoring board (DSMB) will periodically review the safety data and will issue a recommendation if the doses can be used as planned.
This study will consist of:
Up to four dose finding periods, 14 days each:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of PAH (pulmonary arterial hypertension WHO Group 1), documented by right heart catheterisation with a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, a pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg and a pulmonary vascular resistance (PVR) > 3 wood unit (WU):
Exclusion Criteria:
For women: Pregnancy or breast-feeding. Women of unable or unwilling to undergo pregnancy tests and practice acceptable measures from the time of until 30 days after last medicinal product (IMP) intake. Acceptable methods for women are surgical intervention (e.g. bilateral tubal occlusion), non-hormonal implantable intrauterine device, double-barrier methods, true sexual abstinence (i.e. when this is in line with the preferred and usual lifestyle of the patient) and vasectomised partner (provided that the partner is the sole sexual partner of the patient and the partner has received medical assessment of the surgical success). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), hormonal contraceptives and withdrawal are not acceptable methods of contraception.
For men: Male patients who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved acceptable contraceptive measure from the time of informed consent until 90 days after the last IMP intake. The following methods are acceptable methods of contraception: partner's use of combined (oestrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); partner's use of progestogen-only hormonal contraception (oral, injectable/implantable, intrauterine hormone-releasing system); partner's use of implantable intrauterine device; surgical sterilisation (for example, vasectomy or bilateral tubal occlusion).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 mg zamicastat once daily
Drug: Oral zamicastat
100 mg zamicastat once daily
Drug: Oral zamicastat
150 mg zamicastat once daily
Drug: Oral zamicastat
200 mg zamicastat once daily
Drug: Oral zamicastat
Tablets for oral administration under fed conditions containing 100 mg of zamicastat
Also known as: BIA 5-1058
Area Under the Curve 0-24h (AUC0-24h) (ng.h/mL) - 50 mg
This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat
Time frame: Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after investigational medicinal product (IMP) intake)
Area Under the Curve 0-24h (AUC0-24h) (ng.h/mL/mg) - HTD
This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)
Time frame: 1, 2, 4, 8, 16 and 24 hours after IMP intake
Maximum Plasma Concentration (Cmax) (ng/mL) - 50 mg
This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat
Time frame: Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)
Maximum Plasma Concentration (Cmax) (ng/mL/mg) - HTD
This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)
Time frame: 1, 2, 4, 8, 16 and 24 hours after IMP intake
Time Until Cmax (Tmax) (h) - 50 mg
This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat
Time frame: Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)
Time Until Cmax (Tmax) (h) - HTD
This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)
Time frame: 1, 2, 4, 8, 16 and 24 hours after IMP intake
Minimum Plasma Concentration at the End of the Dosing Interval (Cmin,SS) (ng/mL/mg) - HTD
This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD). Following multiple administrations of the HTD of zamicastat to PAH patients at MPV3, PK concentrations and parameter summaries for only the 50 mg, 100 mg and 200 mg dose levels are presented and discussed, as the only subject receiving the 150 mg HTD level had a major protocol deviation documented, impacting the reliability of their PK data.
Time frame: 1, 2, 4, 8, 16 and 24 hours after IMP intake
| Milestone | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Started | 29 | 0 | 0 | 0 |
| Completed | 27 | 0 | 0 | 0 |
| Not completed | 2 | 0 | 0 | 0 |
| Milestone | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Started | 0 | 27 | 0 | 0 |
| Completed | 0 | 21 | 0 | 0 |
| Not completed | 0 | 6 | 0 | 0 |
| Milestone | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Started | 0 | 0 | 21 | 0 |
| Completed | 0 | 0 | 19 | 0 |
| Not completed | 0 | 0 | 2 | 0 |
| Milestone | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 19 |
| Completed | 0 | 0 | 0 | 19 |
| Not completed | 0 | 0 | 0 | 0 |
This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat
| ng.h/mL | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Zamicastat | 155 | 761 ± 44.6 | — | 1570 ± 59.7 |
| BIA 5-453_1 | — | 172 | — | 305 ± 38.5 |
| BIA 5-453_2 | — | 181 | — | 305 ± 38.5 |
| BIA 5-961 | — | 150,187 ± 0 | — | 277 ± 94.3 |
This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)
| ng.h/mL/mg | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Zamicastat | 3.09 | 7.61 ± 44.6 | — | 7.87 ± 59.7 |
| BIA 5-453_1 | — | 1.72 ± 0 | — | 1.53 ± 38.5 |
| BIA 5-453_2 | — | 1.81 | — | 1.53 ± 38.5 |
| BIA 5-961_1 | — | 1.50 | — | 1.39 ± 94.3 |
| BIA 5-961_2 | — | 1.87 | — | 1.39 ± 94.3 |
This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat
| ng/mL | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Zamicastat | 13.3 | 62.6 ± 60.5 | — | 134 ± 94.0 |
| 5-453 | — | 8.39 ± 33.1 | — | 18.8 ± 48.1 |
| BIA 5-961_1 | 5.39 | 11.0 | — | 17.6 ± 78.2 |
| BIA 5-961_2 | 5.39 | 23.9 | — | 17.6 ± 78.2 |
This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)
| ng/mL/mg | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Zamicastat | 0.27 | 0.626 ± 60.5 | — | 0.672 ± 94.0 |
| BIA 5-453 | — | 0.0839 ± 33.1 | — | 0.0939 ± 48.1 |
| BIA 5-961_1 | 0.108 | 0.110 | — | 0.0882 ± 78.2 |
| BIA 5-961_2 | 0.108 | 0.239 | — | 0.0882 ± 78.2 |
This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat
| h | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Zamicastat | 2.00 | 3.00 ± 1.00 | — | 4.00 ± 1.00 |
| BIA 5-453 | — | 3.00 ± 2.00 | — | 4.05 ± 2.00 |
| BIA 5-961 | 4.03 | 2.00 | — | 8.00 ± 4.00 |
This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)
| h | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Zamicastat | 2.00 | 3.00 ± 4.08 | — | 4.00 ± 24.00 |
| BIA 5-453 | — | 3.00 ± 8.08 | — | 4.05 ± 24.0 |
| BIA 5-961 | 4.03 | 8.08 | — | 8.00 ± 24.0 |
This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD). Following multiple administrations of the HTD of zamicastat to PAH patients at MPV3, PK concentrations and parameter summaries for only the 50 mg, 100 mg and 200 mg dose levels are presented and discussed, as the only subject receiving the 150 mg HTD level had a major protocol deviation documented, impacting the reliability of their PK data.
| ng/mL/mg | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Zamicastat | — | 0.186 ± 36.7 | — | 0.198 ± 74.1 |
| BIA 5-453_1 | — | 0.0564 | — | 0.0479 ± 48.5 |
| BIA 5-453_2 | — | 0.0603 | — | 0.0479 ± 48.5 |
| BIA 5-961 | — | 0.0896 | — | 0.0503 ± 58.6 |
Collected over 94,5 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 50 mg Zamicastat | 0/29 (0%) | 0/29 (0%) | 10/29 (34.5%) |
| 100 mg Zamicastat Once Daily | 0/28 (0%) | 2/28 (7.1%) | 15/28 (53.6%) |
| 150 mg Zamicastat Once Daily | 0/27 (0%) | 0/27 (0%) | 15/27 (55.6%) |
| 200 mg Zamicastat Once Daily | 0/21 (0%) | 0/21 (0%) | 11/21 (52.4%) |
| Event | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Device breakageProduct Issues | 0/29 | 1/28 | 0/27 | 0/21 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 0/29 | 1/28 | 0/27 | 0/21 |
| Event | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily |
|---|---|---|---|---|
| Sinus arrhythmiaCardiac disorders | 0/29 | 1/28 | 2/27 | 1/21 |
| NauseaGastrointestinal disorders | 0/29 | 0/28 | 2/27 | 1/21 |
| FatigueGeneral disorders | 1/29 | 1/28 | 2/27 | 1/21 |
| Ventricular extrasystolesCardiac disorders | 0/29 | 2/28 | 0/27 | 0/21 |
| NasopharyngitisInfections and infestations | 1/29 | 2/28 | 0/27 | 0/21 |
| DizzinessNervous system disorders | 0/29 | 2/28 | 0/27 | 0/21 |
| InsomniaPsychiatric disorders | 0/29 | 2/28 | 0/27 | 1/21 |
| HeadacheNervous system disorders | 2/29 | 1/28 | 1/27 | 0/21 |
| SyncopeNervous system disorders | 0/29 | 1/28 | 1/27 | 1/21 |
| Gastrointestinal infectionInfections and infestations | 0/29 | 0/28 | 0/27 | 1/21 |
| Age, Categorical(Participants) | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 6 | 2 | 16 | 25 |
| >=65 years | 0 | 0 | 0 | 3 | 3 |
| Sex: Female, Male(Participants) | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily | Total |
|---|---|---|---|---|---|
| Female | 1 | 5 | 1 | 14 | 21 |
| Male | 0 | 1 | 1 | 5 | 7 |
| Race (NIH/OMB)(Participants) | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 1 | 6 | 2 | 19 | 28 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Height (cm)(Participants) | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily | Total |
|---|---|---|---|---|---|
| <=1.65cm | 0 | 1 | 0 | 12 | 13 |
| >1.65 | 1 | 5 | 2 | 7 | 15 |
| Weight (kg)(Participants) | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily | Total |
|---|---|---|---|---|---|
| <71,5kg | 0 | 3 | 1 | 16 | 20 |
| >71,5kg | 1 | 3 | 1 | 3 | 8 |
| BMI (kg/m2)(Participants) | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily | Total |
|---|---|---|---|---|---|
| <=25,4kg/m2 | 0 | 4 | 2 | 9 | 15 |
| >=25,5kg/m2 | 1 | 2 | 0 | 10 | 13 |
| Childbearing Potential(Participants) | 50 mg Zamicastat | 100 mg Zamicastat Once Daily | 150 mg Zamicastat Once Daily | 200 mg Zamicastat Once Daily | Total |
|---|---|---|---|---|---|
| Yes | 0 | 4 | 1 | 6 | 11 |
| No | 1 | 2 | 0 | 8 | 11 |
| Not Applicable | 0 | 0 | 1 | 5 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2019 to primary completion in Oct 2021, 28 months.
Results were first posted in Oct 2024, 2 years 11 months after primary completion.
Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 28 months is close to that.
Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zamicastat
Pulmonary Arterial Hypertension →